1.Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
Luis Felipe SALLUM ; Luis Otavio SARIAN ; Liliana LUCCI DE ANGELO ANDRADE ; Jose VASSALLO ; Fernando Augusto SOARES ; Glauce Aparecida PINTO ; Patricia Andreia FERREIRA ; Sophie DERCHAIN
Journal of Gynecologic Oncology 2013;24(2):167-176
OBJECTIVE: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. METHODS: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. RESULTS: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). CONCLUSION: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.
Disease-Free Survival
;
Estrogens
;
Female
;
Humans
;
Immunohistochemistry
;
Mucins
;
Progesterone
;
Receptors, Progesterone
;
Receptors, Steroid
2.Stage and histology of cervical cancer in women under 25 years old
Diama Bhadra VALE ; Lucas Almeida CAVALCANTE ; Liliana Aparecida Lucci De Angelo ANDRADE ; Julio Cesar TEIXEIRA ; Talita Lourenço do Rio MENIN ; Luiz Carlos ZEFERINO
Journal of Gynecologic Oncology 2019;30(4):e55-
OBJECTIVE: To evaluate the histological and stage characteristics of cervical cancer in women under 25 years old, and to compare them with older women. METHODS: Cross-sectional study of cases from the Hospital Cancer Registry of São Paulo State/Brazil from 2000 to 2015. Variables were age, International Federation of Gynecology and Obstetrics stage and histological type. Prevalence ratio (PR) and its 95% confidence interval (CI) were calculated. RESULTS: Out of 18,423 cervical cancer cases 204 (1.1%) were in women under 25 years old. The most frequent stage was stage I in women under 25 (36.2%) and between 25 and 34 (43.4%), and stage III in older women (31.8%). No statistically significant difference was observed in stages by age group. Squamous carcinomas were the most frequent in 73.5% of women under 25 and 78.5% of older women. In women under 25 the following histological types were more frequent: neuroendocrine carcinomas (PR=6.10, 95% CI=2.03–18.35), malignant germ cell tumors (PR=54.98, 95% CI=26.53–113.95), mesenchymal tumors (sarcomas) (PR=5.67, 95% CI=2.58–12.45) and hematopoietic/lymphoid tumors (PR=0.72, 95% CI=2.90–36.69). CONCLUSION: In women under 25 years old cervical cancer was an uncommon diagnosis and in about one third occurred at early stage. Squamous carcinoma was the most frequent histological type regardless age, but rare histological types were more frequent in young women.
Carcinoma, Neuroendocrine
;
Carcinoma, Squamous Cell
;
Cross-Sectional Studies
;
Diagnosis
;
Female
;
Gynecology
;
Humans
;
Neoplasm Staging
;
Neoplasms, Germ Cell and Embryonal
;
Obstetrics
;
Prevalence
;
Sarcoma
;
Uterine Cervical Neoplasms
;
Young Adult